CD276 and neoplasm: Notably, 100% of animals challenged with ER−, PR− HER2− SUM159 and MDA-MB-231 tumors exhibited complete and sustained tumor regression 6 months post treatment, suggesting that CD276 could be a critical target for triple-negative breast cancer (TNBC).